Nilesh Shah, Managing Director & CEO of Envision Capital, discusses how much further Indian markets could rally on the back of election euphoria.» Read More
Dec 4- Oculus Innovative Sciences Inc's shares more than doubled after the U.S. Food and Drug Administration approved the company's anti-scar treatment for raised and red scars resulting from burns, surgical procedures and trauma wounds. This is the eighth FDA approval for Microcyn-based products, Oculus CEO Jim Schutz said in a statement on Wednesday.
*Cuts full-year earnings/share view to $1.46- $1.51 vs est $1.61. Dec 4- Apparel retailer Express Inc joined other U.S. retailers in forecasting a weaker-than-expected holiday quarter due to muted Thanksgiving sales and a highly promotional environment.
Dec 4- Apparel retailer Express Inc forecast current-quarter earnings below analysts' estimates, blaming weaker-than-expected Thanksgiving sales, sending its shares down 8 percent in premarket trading. The company said it expects a profit of 66- 71 cents per share for the fourth quarter ending Feb. 1, 2014.
Dec 2- Cognizant Technology Solutions Corp will hire at least 10,000 people in the United States over the next three years, the IT services firm's president, Gordon Coburn, said.
*First-quarter revenue $2.02 bln vs estimate of $2.01 bln. May 8- Cognizant Technology Solutions Corp forecast current-quarter revenue above market expectations after an 18 percent rise in the first quarter, helped by strong demand from Europe. First-quarter sales from Europe rose 23 percent, outpacing a 16 percent growth in North America.
Sunil Kant Munjal, joint managing director of Hero Motocorp and chairman of Hero Corporate Service, says Africa is an attractive market as the company looks to grow.
Sunil Kant Munjal, joint managing director of Hero Motocorp and chairman of Hero Corporate Service, says Indians are frustrated with the pace of reform and a new government will be key to implementing reform.
Sunil Kant Munjal, Managing Director, Hero Motors, describes the state of the Indian economy and outlook for regional political parties.
Indians are frustrated by the slow pace of government reforms to reignite the country's growth, said the head of Hero MotoCorp.
It's election season in India and CNBC's Geoff Cutmore is live in New Delhi as the capital city holds its assembly poll, which is viewed as a warm-up to general elections.
CNBC's Lisa Oake reports live in Bali at the World Trade Organization (WTO) meeting after India's commerce minister called the agricultural deal on the table "half-baked."
NEW DELHI, Dec 4- The broken paving stones and exposed cables that mar the neo-Georgian grandeur of India's prime shopping precinct give a glimpse into why the ruling Congress party might struggle to hold on to the capital Delhi in a local election on Wednesday.
Bertrand Badre, Chief Financial Officer at the World Bank, describes his view on emerging market nations like India and Indonesia.
Dec 3- J.C. Penney Co Inc said on Tuesday that comparable-store sales rose in November for the second straight month, as its aggressive discounts and the return of some in-house brands brought back shoppers at the start of the holiday quarter.
Dec 3- An Abercrombie& Fitch Co shareholder urged the teen apparel retailer to replace Chief Executive Mike Jeffries after his contract expires in February, failing which the company should look to sell itself.
*Celgene to take 5 pct stake in OncoMed. *Celgene stock down 1.4 pct. Dec 3- Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.
Dec 3- An Abercrombie& Fitch Co shareholder called on the teen apparel retailer to replace Chief Executive Mike Jeffries after his contract expires in February, saying his re-election could further dent shareholder confidence in the board.
Dec 3- Shares of OncoMed Pharmaceuticals Inc soared almost 90 percent in premarket trading after the company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs. Celgene will also buy about $22.25 million of OncoMed's common stock for $15.13 per share, giving it a stake of about 5 percent in the company.
Economic expansion, nuclear plant shutdowns in Japan and South Korea and the shift toward cleaner-burning gas in smog-choked Chinese cities have contributed to rising demand for LNG in Asia, already the top destination for the fuel.
Dec 3- OncoMed Pharmaceuticals Inc said Celgene Corp would develop and market six of its anti-cancer stem cell experimental drugs for an upfront payment of $155 million. OncoMed is eligible to receive up to $3 billion in option and milestone payments if Celgene's option to license worldwide rights is exercised and approved, the companies said in a statement.